Rheumatology International

, Volume 6, Issue 5, pp 221–226 | Cite as

Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course

  • A. J. G. Swaak
  • A. van Rooyen
  • C. Vogelaar
  • M. Pillay
  • E. Hack
Originals

Summary

Metabolic turnover studies of complement components (C3) provide a direct insight into the dynamics of the complement regulation (synthesis and catabolism). To obtain information about the role of the complement system in relation to the disease course in patients with systemic lupus erythematosus (SLE), a prospective study was performed. The results of the C3 turnover studies were also correlated to the complement levels (C3) and to the presence of C3 conversion products (C3d) in circulation. In nearly all SLE patients (in 21 of the 26 metabolic turnover studies) a C3 hypercatabolism was found, with a quantitative difference depending on the disease phase. In the period preceding an exacerbation an impaired C3 synthesis was observed (in three of the four studies), in contrast to SLE patients in stable disease phase where in one case only a decrease C3 synthesis was calculated (1 out of 15 observations). A linear correlation was found between the serum C3-levels and the ratio of C3d/C3, suggesting that both serologic parameters are quantitatively indicative for C3 hypercatabolism. The study shows that in all SLE patients, irrespective of the disease stage, an increased C3 consumption is found, which supports the concept that a chronic inflammatory process is constantly present.

Key words

Fractional catabolic rate Synthetic rate C3 conversion products C3d 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Swaak AJG, Aarden LA, Statius van Eps LW, Feltkamp TEW (1979) Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 22:226–235Google Scholar
  2. 2.
    Schur PH, Austen KF (1971) Complement in the rheumatic diseases. Bull Rheum Dis 22:666–673Google Scholar
  3. 3.
    Lewis EJ, Carpenter CB, Shur PH (1971) Serum complement components levels in human glomerulonephritis. Ann Intern Med 75:555–560Google Scholar
  4. 4.
    Schur PH (1975) Complement in lupus. Clin Rheum Dis 1:519–543Google Scholar
  5. 5.
    Perrin LH, Lambert PH, Miescher PA (1974) Properdin levels in systemic lupus erythematosus and membrano-proliferative glomerulonephritis. Clin Exp Immunol 16:575–581Google Scholar
  6. 6.
    Williams DG, Peters DK, Fallows S, Petric A, Kovritsby A, Morel-Moroger L, Cameron JS (1974) Studies of serum complement in the hypocomplementemic nephritis. Clin Exp Immunol 18:391–405Google Scholar
  7. 7.
    Hunsicker CLG, Ruddy S, Carpenter CB, Schur PH, Merrill JP, Müller-Eberhard HJ, Austen KF (1972) Metabolism of third complement component (C3) in nephritis. N Engl J Med 287:835–840Google Scholar
  8. 8.
    Ruddy S, Carpenter CB, Chin KW, Knostman JN, Soter MA, Götze O, Müller-Eberhard HJ, Austen KF (1975) Human complement metabolism: an analysis of 144 studies. Medicine (Baltimore) 54:165–178Google Scholar
  9. 9.
    Petz LD, Powers R, Fries JR, Cooper NR, Holman HR (1977) The in vivo metabolism of the third component of complement in systemic lupus erythematosus. Arthritis Rheum 1304–1313Google Scholar
  10. 10.
    Swaak AJG, Groenwold J, Aarden LA, Statius van Eps LW, Feltkamp TEW (1982) Prognostic value of anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 41:388–395Google Scholar
  11. 11.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schuller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277Google Scholar
  12. 12.
    Lightfoot RW, Hughes GRV (1976) Significance of persisting serologic abnormalities in SLE. Arthritis 19:837–843Google Scholar
  13. 13.
    Matthews CME (1957) The theory of tracer experiments with 125I-labelled plasma proteins. Phys Med Biol 2:36–53Google Scholar
  14. 14.
    Molenaar JL, Müller M, Pondman KW (1973) A new preparative method for isolation of human C3 using affinity chromatography. J Immunol 110:1570–1586Google Scholar
  15. 15.
    Müller-Eberhard HJ, Dalmasso AP, Calcott MA (1966) The reaction mechanism of B1C-' globulin (C'3) in immune hemolysis.. J Exp Med 123:33–54Google Scholar
  16. 16.
    Charlesworth JA, Williams DG, Naish P, Lachmann PJ, Peters DK (1974) Metabolism of radio-labelled C3 effects of in vivo activation in rabbits. Clin Exp Immunol 16:445–452Google Scholar
  17. 17.
    Swaak AJG, Hannema A, Vogelaar C, Boom FA, Es L van, Aalst R van, Statius van Eps LW (1982) Determination of the half-life of C3 in patients and its relation to the presence of C3 breakdown products and/or circulating immune complexes. Rheumatol Int 2:161–166Google Scholar
  18. 18.
    Alper CA, Rosen FS (1967) Studies of the in vivo behavior of human C3 in normal subjects and patients. J Clin Invest 46:2021–2034Google Scholar
  19. 19.
    Espejo RT, Canelo ES (1968) Properties of bacteriophage PM2: a lipid containing bacterial virus. Virology 34:738–747Google Scholar
  20. 20.
    Aarden LA, Lakmaker F, Feltkamp TEW (1976) Immunology of DNA II. The effect of size and structure of the antigen in the Farr assay. J Immunol Methods 10:39–48Google Scholar
  21. 21.
    Aarden LA, Lakmaker F, de Groot ER (1976) Immunology of DNA IV. Quantitative aspects of the Farr assay. J Immunol Methods 11:153–163Google Scholar
  22. 22.
    Townes AS, Stewart CR, Oster AG (1962) Immunologic studies of systemic lupus erythematosus. John Hopkins Med J 112:202–218Google Scholar
  23. 23.
    Swaak AJG, Groenwold J, Bronsveld W (1986) The predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45:359–366Google Scholar
  24. 24.
    Perrin LH, Nydegge UE, Zubler RH, Lambert PH, Miescher PA (1977) correlation between levels of breakdown products of C3, C4 and properdin factor B in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 20:647–652Google Scholar
  25. 25.
    Peters DK, Martin A, Weinstein A, Cameron JS, Barlett TM, Ogg CS, Lachmann Pj (1972) Complement studies in membrane-proliferative glomerulonephritis. Clin Exp Immunol 11:371–373Google Scholar
  26. 26.
    Charlesworth JA, Gwyn Williams D, Scherington E, Lachman PJ, Peters DK (1974) Metabolic studies of the third component of complement and the glycine-rich beta-glycoprotein in patients with hypocomplementernia. J Clin Invest 53:1578–1587Google Scholar
  27. 27.
    Sissons JGP, Liebowitch J, Amos N, Peters DK (1977) Metabolism of the fifth component of complement, and its relation to metabolism of the third component in patients with complement activation. J Clin Invest 59:704–715Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • A. J. G. Swaak
    • 1
  • A. van Rooyen
    • 2
  • C. Vogelaar
    • 2
  • M. Pillay
    • 3
  • E. Hack
    • 2
  1. 1.Department of RheumatologyThe Dr. Daniel den Hoed Cancer CenterRotterdamThe Netherlands
  2. 2.Department of Auto-Immune DiseaseCentral Laboratory of the Blood Transfusion ServiceNL-AmsterdamThe Netherlands
  3. 3.Department of Nuclear Medicine and RadiopharmacologyThe Dr. Daniel den Hoed Cancer CenterNL-RotterdamThe Netherlands

Personalised recommendations